Clinical Trials (PDQ®)
|Phase I||Biomarker/Laboratory analysis, Prevention||Active||40 to 79||NCI, Other||CDR0000596506|
P30CA016056, RPCI-I-90206, I 90205, NCT00690924
RATIONALE: Calcitriol may prevent lung cancer in patients with metaplasia or dysplasia of the lungs.
PURPOSE: This clinical trial is studying the side effects and best dose of calcitriol in preventing lung cancer in current smokers and former smokers at high risk of lung cancer.
Further Study Information
- To establish the safety of calcitriol in patients at high risk of lung cancer.
- To determine the dose-limiting toxicities of calcitriol in these patients.
OUTLINE: Patients receive oral calcitriol on day 1. Courses repeat every 2 weeks for 3 months in absence of unacceptable toxicity.
Patients undergo blood collection periodically for pharmacokinetic and molecular analysis.
After completion of study therapy, patients are followed periodically.
- Pathologically confirmed squamous metaplasia or squamous dysplasia of the lungs by autofluorescence bronchoscopy within the past 5 years
- Must be a current or former smoker
- No evidence of concurrent disease with lung cancer or head and neck cancer
- History of treated lung cancer or head and neck cancer treated with curative intent allowed, provided that there has been no evidence of disease for > 1 year
- ECOG performance status 0-1
- Total granulocyte count > 1,500 x 10^9cells/L
- Platelet count > 100,000 x 10^9cells/L
- Calculated Creatinine clearance > 60 mL/min (using the Cockcroft-Gault formula)
- Calcium concentration 50-300 mg/24 hours
- Total bilirubin 0.2-1.3 mg%
- ALT/AST ≤ 2.5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2.5 times ULN
- Albumin ≥ 2.5 g/dL
- Ionized serum calcium normal (1.19-1.29 mmol/L)
- Corrected serum calcium ≤ 10.2 mg/dL
- Willing to attend all scheduled study visits, complete all study questionnaires, and allow biological specimen collection, including a bronchoscopy
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for at least 1 month after completion of study therapy
- No life-threatening medical conditions that would preclude bronchoscopy, including but not limited to, any of the following:
- Acute cardiac failure
- Uncontrolled hypertension
- Uncontrolled diabetes mellitus
- Unstable coronary artery disease
- No severe metabolic disorders that would preclude calcitriol administration
- No history of any other malignancy within 3 years except for nonmelanoma skin cancer or cervical carcinoma in situ
- No history or evidence of kidney stones
- No patients who are susceptible to calcium-related dysrhythmias
- No known hypersensitivity to calcitriol
- No known allergies to tree nuts (i.e., almonds)
PRIOR CONCURRENT THERAPY:
- At least 2 months since prior and no concurrent calcium supplements
- Concurrent multivitamin supplement allowed provided the amount of vitamin D in the supplement is not in excess of the recommended daily dose
- No concurrent thiazides, phenobarbital, or digitalis
- No concurrent digoxin
- No concurrent bile acid binding drugs (i.e., cholestyramine, colestipol)
- No concurrent danazol or aluminum-based antacids
- No concurrent ketoconazole or other azole antifungals
Trial Lead Organizations/Sponsors
Roswell Park Cancer InstituteNational Cancer Institute
|Alex A. Adjei||Principal Investigator|
|Roswell Park Cancer Institute|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00690924
ClinicalTrials.gov processed this data on October 20, 2014
Back to Top